Remove sarepta-enjoys-early-sales-ramp-dmd-gene-therapy-maintains-confidence-label-expansion
article thumbnail

Sarepta enjoys early sales ramp for DMD gene therapy, maintains confidence in label expansion

Fierce Pharma

The third quarter marked a momentous one for Sarepta Therapeutics, bringing the long-anticipated launch of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys. Even before a potential label expansion, the gene therapy Elevidys has raked in around $69 million since its launch.

Sales 248